Free tool
FAERS Monitor: Zarxio
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125553 or its brand name (Zarxio, Filgrastim-Sndz). Reports on generic versions are filed under their own applications.
Reports
3,331
Serious
1,898
57% of reports
Hospitalization
676
Death reported
751
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death635
- fatigue174
- white blood cell count decreased169
- diarrhoea136
- nausea116
- off label use95
- hospitalisation92
- pyrexia91
- neutropenia86
- platelet count decreased76
- asthenia75
- bone pain74
- rash73
- pneumonia71
- neoplasm malignant68
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 56 |
| 2017 | 123 |
| 2018 | 263 |
| 2019 | 372 |
| 2020 | 532 |
| 2021 | 706 |
| 2022 | 379 |
| 2023 | 337 |
| 2024 | 270 |
| 2025 | 171 |
| 2026 | 121 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,828 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| white blood cell count decreasedSignal | 169 | 9.9 | 8.5 | 1,341 |
| bone painSignal | 74 | 8.0 | 6.4 | 446 |
| neoplasm malignantSignal | 68 | 6.4 | 5.1 | 308 |
| deathSignal | 635 | 4.7 | 4.3 | 1,896 |
| platelet count decreasedSignal | 76 | 4.5 | 3.6 | 205 |
| neutropeniaSignal | 86 | 4.0 | 3.2 | 191 |
| hospitalisationSignal | 92 | 3.8 | 3.1 | 187 |
| pyrexia | 91 | 1.7 | 1.4 | 24 |
| fatigue | 174 | 1.4 | 1.2 | 21 |
| pneumonia | 71 | 1.4 | 1.1 | 7 |
| diarrhoea | 136 | 1.3 | 1.1 | 11 |
| asthenia | 75 | 1.3 | 1.0 | 4 |
| rash | 73 | 1.1 | 0.8 | 0 |
| nausea | 116 | 0.9 | 0.8 | 1 |
| off label use | 95 | 0.7 | 0.6 | 14 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.